ZA99407B - Extended release tiagabine formulations with reduced side-effects. - Google Patents

Extended release tiagabine formulations with reduced side-effects.

Info

Publication number
ZA99407B
ZA99407B ZA9900407A ZA99407A ZA99407B ZA 99407 B ZA99407 B ZA 99407B ZA 9900407 A ZA9900407 A ZA 9900407A ZA 99407 A ZA99407 A ZA 99407A ZA 99407 B ZA99407 B ZA 99407B
Authority
ZA
South Africa
Prior art keywords
effects
extended release
reduced side
formulations
release tiagabine
Prior art date
Application number
ZA9900407A
Other languages
English (en)
Inventor
Francisco J Alvarez
Russell T Slade
Kathleen M Apfelbaum
David M Brown
Linda E Gustavson
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA99407B publication Critical patent/ZA99407B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9900407A 1998-01-22 1999-01-20 Extended release tiagabine formulations with reduced side-effects. ZA99407B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7213098P 1998-01-22 1998-01-22

Publications (1)

Publication Number Publication Date
ZA99407B true ZA99407B (en) 1999-07-20

Family

ID=22105780

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900407A ZA99407B (en) 1998-01-22 1999-01-20 Extended release tiagabine formulations with reduced side-effects.

Country Status (23)

Country Link
US (1) US20070053980A1 (hu)
EP (1) EP1049470B1 (hu)
JP (1) JP2002501022A (hu)
KR (1) KR20010034313A (hu)
CN (1) CN1145484C (hu)
AR (1) AR018041A1 (hu)
AT (1) ATE350035T1 (hu)
AU (1) AU2239599A (hu)
BG (1) BG104692A (hu)
CA (1) CA2318448A1 (hu)
CO (1) CO4970814A1 (hu)
DE (1) DE69934670D1 (hu)
HU (1) HUP0101739A3 (hu)
IL (1) IL137324A0 (hu)
NO (1) NO20003677L (hu)
NZ (1) NZ505725A (hu)
PL (1) PL194595B1 (hu)
SA (1) SA99200204B1 (hu)
SK (1) SK11072000A3 (hu)
TR (2) TR200002102T2 (hu)
TW (1) TW585787B (hu)
WO (1) WO1999037302A1 (hu)
ZA (1) ZA99407B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872734B2 (en) 2000-10-20 2005-03-29 Abbott Laboratories Use of tiagabine for treatment of diabetic neuropathy and migraine
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JP3195360B2 (ja) * 1995-05-05 2001-08-06 ノボ ノルディスク アクティーゼルスカブ チアガビン塩酸塩を含有する医薬組成物およびその製法
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
WO1999006045A1 (en) * 1997-08-01 1999-02-11 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting

Also Published As

Publication number Publication date
IL137324A0 (en) 2001-07-24
SA99200204B1 (ar) 2006-10-11
PL342767A1 (en) 2001-07-02
AU2239599A (en) 1999-08-09
TR200002102T2 (tr) 2000-12-21
PL194595B1 (pl) 2007-06-29
AR018041A1 (es) 2001-10-31
ATE350035T1 (de) 2007-01-15
CN1145484C (zh) 2004-04-14
NZ505725A (en) 2003-01-31
EP1049470B1 (en) 2007-01-03
CO4970814A1 (es) 2000-11-07
JP2002501022A (ja) 2002-01-15
EP1049470A1 (en) 2000-11-08
HUP0101739A3 (en) 2002-10-28
KR20010034313A (ko) 2001-04-25
DE69934670D1 (de) 2007-02-15
TW585787B (en) 2004-05-01
CN1293571A (zh) 2001-05-02
BG104692A (en) 2001-05-31
US20070053980A1 (en) 2007-03-08
SK11072000A3 (sk) 2001-01-18
NO20003677L (no) 2000-09-20
WO1999037302A1 (en) 1999-07-29
TR200505223T2 (tr) 2006-04-21
HUP0101739A2 (hu) 2002-03-28
CA2318448A1 (en) 1999-07-29
NO20003677D0 (no) 2000-07-18

Similar Documents

Publication Publication Date Title
ZA993938B (en) Ziprasidone formulations.
HK1047942A1 (en) Purine derivatives.
HK1047111A1 (en) Purine derivatives.
ZA200202849B (en) Purine derivatives.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
HK1034478A1 (en) Game system.
ZA99254B (en) Benzosulfone derivatives.
HK1051037A1 (en) Benzodiazepine derivatives.
ZA200202544B (en) Benzodiazepine derivatives.
ZA995445B (en) Extended release buccal tablet.
ZA200005136B (en) Dihydropyrimides.
HK1034978A1 (en) Adenosine derivatives.
ZA200202537B (en) Pour-on-formulations.
GB0030757D0 (en) Equi-pressure geosteering
HK1049798A1 (en) Solid lipid formulations.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
HK1051199A1 (en) New phenylpiperazines.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
ZA200006352B (en) Compound napkin.
HK1034969A1 (en) Dihydroxyhexanoic acid derivatives.
ZA992322B (en) Phosphodiesterase iv-inhibiting diazepinoindoles.
ZA991550B (en) Cyclohexanediole derivatives.
ZA99407B (en) Extended release tiagabine formulations with reduced side-effects.
ZA200204581B (en) Nitro-sulfobenzamides.
AU2002325404A1 (en) Extended Release Tiagabine Formulations with Reduced Side-effects